ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: Carbone To Leave NCI for Wisconsin ACS’ Holleb Says Tobacco Industry Tries to Hide Ad Warning

October 3, 1975

Hammer Blast GAO Report As ”Gobblygook”

June 12, 1987

St. Jude Children’s wins NCI contract for Pediatric Preclinical Testing Program.

November 12, 2004

Disease Oriented Programs Must Be Coordinated: Rabson

October 15, 1976

Amgen Says It Can Demonstrate Safety of Existing Hg Target.

March 16, 2007

Professional Societies: ASCO opposes FDA On Stem Cell Transplant Regs

May 16, 1997